Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrotic Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SERPINE2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPINE2 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). HEK293 Expressed for native glycosylation. Sequence Verified. |
View SERPINE2 Products |
| Gene Delivery | SERPINE2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based conformation preservation. |
View SERPINE2 Products |
| Benchmark Ab | Anti-SERPINE2 Recombinant Antibody Recombinant positive control for assay validation. Sequence verified. |
View SERPINE2 Products |
| Validator | SERPINE2 siRNA Set For target knockdown verification and target validation assays. |
View SERPINE2 Products |
| Related Target A | LRP1 Low-density lipoprotein receptor-related protein 1. Mediates the clearance of SERPINE2-protease complexes; critical for endocytosis assays. |
View LRP1 Products |
| Related Target B | PLAU Urokinase-type plasminogen activator (uPA). Primary serine protease target of SERPINE2 in cancer metastasis pathways. |
View PLAU Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent activity validation | HEK293 Expressed proteins ensuring native post-translational modifications and correct folding |
| Subfamily cross-reactivity screening (e.g., SERPINE1 counter-screening) | High-purity homologous serpin panels strictly verified by mass spectrometry and SDS-PAGE |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives | Sequence-verified siRNA sets included for target specificity validation |
Live SERPINE2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SERPINE2 (also known as Protease Nexin-1 or PN-1) is emerging as a highly promising strategy in oncology, particularly in pancreatic ductal adenocarcinoma (PDAC), breast cancer, and colorectal cancer, as well as in chronic inflammatory and fibrotic disorders. As a key serine protease inhibitor, SERPINE2 regulates extracellular matrix (ECM) remodeling, tumor cell invasion, and angiogenesis by blocking proteases like uPA, tPA, and thrombin.
The race for SERPINE2 therapeutics is intensifying, with major players shifting focus from traditional systemic protease inhibitors to highly selective monoclonal antibodies and nucleic acid therapeutics. As first-generation therapies targeting the tumor microenvironment reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions between SERPINE2 and its clearance receptor, LRP1, to modulate local extracellular concentrations of active proteases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Startups | Pancreatic Cancer, Metastatic Breast Cancer | Epitope mapping & binding kinetics (Need HEK293-expressed native SERPINE2) |
| siRNA / RNAi | RNA Therapeutics Specialists | Pulmonary Fibrosis, COPD | Target knockdown validation (Need sequence-verified siRNA sets) |
| Small Molecule Inhibitors | Oncology-focused Pharma | Solid Tumors (Microenvironment modulation) | Enzymatic inhibition assays (Need functional protease-serpin binding validation) |